Reinfection following initial cerebrospinal fluid shunt infection.
OBJECTIVE
Significant variation exists in the surgical and medical management of CSF shunt infection. The objectives of this study were to determine CSF shunt reinfection rates following initial CSF shunt infection in a large patient cohort and to determine management, patient, hospital, and surgeon factors associated with CSF shunt reinfection.


METHODS
This retrospective cohort study included children who were in the Pediatric Health Information System (PHIS) database, who ranged in age from 0 to 18 years, and who underwent uncomplicated initial CSF shunt placement in addition to treatment for initial CSF shunt infection between January 1, 2001, and December 31, 2008. The outcome was CSF shunt reinfection within 6 months. The main predictor variable of interest was surgical approach to treatment of first infection, which was determined for 483 patients. Covariates included patient, hospital, surgeon, and other management factors.


RESULTS
The PHIS database includes 675 children with initial CSF shunt infection. Surgical approach to treatment of the initial CSF shunt infection was determined for 483 children (71.6%). The surgical approach was primarily shunt removal/new shunt placement (in 286 children [59.2%]), but a substantial number underwent externalization (59 children [12.2%]), of whom a subset went on to have the externalized shunt removed and a new shunt placed (17 children [3.5% overall]). Other approaches included nonsurgical management (64 children [13.3%]) and complete shunt removal without shunt replacement (74 children [15.3%]). The 6-month reinfection rate was 14.8% (100 of 675 patients). The median time from infection to reinfection was 21 days (interquartile range [IQR] 5-58 days). Children with reinfection had less time between shunt placement and initial infection (median 50 vs 79 days, p = 0.06). No differences between those with and without reinfection were seen in patient factors (patient age at either shunt placement or initial infection, sex, race/ethnicity, payer, indication for shunt, number of comorbidities, distal shunt location, and number of shunt revisions at first infection); hospital volume; surgeon volume; or other management factors (for example, duration of intravenous antibiotic use). Nonsurgical management was associated with reinfection, and complete shunt removal was negatively associated with reinfection. However, reinfection rates did not differ between the 2 most common surgical approaches: shunt removal/new shunt placement (44 [15.4%] of 286; 95% CI 11.4%-20.1%) and externalization (total 12 [20.3%] of 59; 95% CI 11.0%-32.8%). Externalization followed by shunt removal/new shunt placement (5 [29.4%] of 17; 95% CI 10.3%-56.0%) and nonsurgical management (15 [23.4%] of 64; 95% CI 13.8%-35.7%) had higher, but nonstatistically significant, reinfection rates. The length of stay was shorter for nonsurgical management.


CONCLUSIONS
Surgical approach to treatment of initial CSF shunt infection was not associated with reinfection in this large cohort of patients.
Simon
Tamara D
TD
Division of Inpatient Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA. Tamara.Simon@hsc.utah.edu
Hall
Matthew
M
Dean
J Michael
JM
Kestle
John R W
JR
Riva-Cambrin
Jay
J
D002557:Cerebrospinal Fluid Shunts; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007239:Infections / Q000209:etiology* / Q000601:surgery*; D008297:Male; D011183:Postoperative Complications; D012008:Recurrence; D012189:Retrospective Studies; D013514:Surgical Procedures, Operative / Q000379:methods; D013997:Time Factors
Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1056-8
7889968
Pediatrics. 2000 Jul;106(1 Pt 2):205-9
10888693
Pediatr Neurosurg. 2001 Oct;35(4):205-10
11694798
J Neurosurg. 2007 Nov;107(5 Suppl):345-57
18459897
Clin Infect Dis. 1993 Jan;16(1):139-41
8448291
Pediatrics. 2001 Jun;107(6):E99
11389297
Med Clin North Am. 1985 Mar;69(2):297-314
3990436
Clin Infect Dis. 1992 Aug;15(2):285-9
1387805
Clin Infect Dis. 1999 May;28(5):1134-8
10452648
Am J Dis Child. 1978 May;132(5):480-3
645674
Neurol Clin. 2003 Nov;21(4):883-95, vii
14743654
Curr Clin Top Infect Dis. 1988;9:185-214
3077288
Childs Brain. 1975;1(5):306-10
1175443
Am J Dis Child. 1984 Dec;138(12):1103-8
6507392
Pediatrics. 1977 Apr;59(4):614-8
850601
J Neurosurg. 1984 May;60(5):1014-21
6716136
Pediatr Infect Dis. 1984 May-Jun;3(3 Suppl):S30-2
6739339
J Antimicrob Chemother. 1987 Feb;19(2):249-53
3571045
J Neurosurg. 1984 Feb;60(2):354-60
6607326
Med Care. 2000 Aug;38(8):868-76
10929998
J Neurosurg Pediatr. 2009 Aug;4(2):156-65
19645551
Childs Nerv Syst. 2006 Jul;22(7):692-7
16534646
Infect Dis Clin North Am. 1989 Jun;3(2):289-99
2663983
Clin Pharm. 1987 Nov;6(11):866-80
3315400
Pediatr Neurosurg. 2001 Aug;35(2):66-71
11549916
J Neurosurg. 2006 Sep;105(3 Suppl):177-81
16970229
Br J Neurosurg. 1992;6(5):501-4
1333229
Neurosurg Clin N Am. 1992 Apr;3(2):343-54
1633464
J Neurosurg. 1979 Dec;51(6):804-11
501424
J Infect Dis. 1987 Oct;156(4):548-54
3624904
J Neurosurg Pediatr. 2008 Feb;1(2):131-7
18352782
Pediatr Neurosurg. 2002 May;36(5):248-55
12053043
J Neurosurg. 2001 Feb;94(2):195-201
11213954
Ann Pharmacother. 2005 May;39(5):949-52
15811909
Am J Hosp Pharm. 1980 Feb;37(2):268-71
6987866
Can J Neurol Sci. 1993 May;20(2):118-22
8334572
Neurosurgery. 2006 Apr;58(4):657-65; discussion 657-65
16575329
Z Kinderchir. 1984 Dec;39 Suppl 2:111-3
6524101
Pediatr Neurosurg. 2003 Dec;39(6):285-90
14734861
Pediatr Neurosurg. 1999 Jun;30(6):288-95
10494054